Warner Chilcott, Impax, Mylan infectious news
Warner Chilcott said the U.S. District Court for the District of New Jersey ruled in favor of Mylan and Impax in a patent infringement suit brought by Warner Chilcott related to a generic version of 150 mg Doryx doxycycline delayed-release tablets. Although the court upheld the validity of U.S. Patent No. 6,958,161 covering Doryx, the court said that Mylan's and Impax's generic versions of Doryx do not infringe the patent, which expires in 2022. Mylan immediately began shipping its Doxycycline Hyclate Delayed-release (DR) Tablets following the decision. Warner Chilcott has U.S. marketing rights to the tetracycline oral antibiotic from Mayne Pharma Group Ltd. (ASX:MYX, Melbourne, Australia). Warner Chilcott, which said it is reviewing the courts decision and plans to appeal the non-infringement determination, plans to record a $90-$108 million impairment charge in connection with the ruling. ...